company background image
MSB

Mesoblast ASX:MSB Stock Report

Last Price

AU$0.86

Market Cap

AU$604.4m

7D

-2.8%

1Y

-57.4%

Updated

09 Aug, 2022

Data

Company Financials +
MSB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

MSB Stock Overview

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland.

Mesoblast Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mesoblast
Historical stock prices
Current Share PriceAU$0.86
52 Week HighAU$2.08
52 Week LowAU$0.61
Beta2.57
1 Month Change4.22%
3 Month Change-13.07%
1 Year Change-57.39%
3 Year Change-41.55%
5 Year Change-49.86%
Change since IPO8.13%

Recent News & Updates

Jun 06
Does Mesoblast (ASX:MSB) Have A Healthy Balance Sheet?

Does Mesoblast (ASX:MSB) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Shareholder Returns

MSBAU BiotechsAU Market
7D-2.8%0.1%0.7%
1Y-57.4%-1.3%-8.0%

Return vs Industry: MSB underperformed the Australian Biotechs industry which returned -1.3% over the past year.

Return vs Market: MSB underperformed the Australian Market which returned -8% over the past year.

Price Volatility

Is MSB's price volatile compared to industry and market?
MSB volatility
MSB Average Weekly Movement9.3%
Biotechs Industry Average Movement11.7%
Market Average Movement10.5%
10% most volatile stocks in AU Market17.6%
10% least volatile stocks in AU Market4.6%

Stable Share Price: MSB is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: MSB's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200483Silviu Itescuhttps://www.mesoblast.com

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

Mesoblast Limited Fundamentals Summary

How do Mesoblast's earnings and revenue compare to its market cap?
MSB fundamental statistics
Market CapUS$423.08m
Earnings (TTM)-US$91.95m
Revenue (TTM)US$9.98m

39.4x

P/S Ratio

-4.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MSB income statement (TTM)
RevenueUS$9.98m
Cost of RevenueUS$79.74m
Gross Profit-US$69.76m
Other ExpensesUS$22.19m
Earnings-US$91.95m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.14
Gross Margin-698.78%
Net Profit Margin-921.09%
Debt/Equity Ratio18.2%

How did MSB perform over the long term?

See historical performance and comparison